Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Sep 23, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K filing on 9/23, likely with news.
AI Summary
Innate Pharma SA filed a Form 6-K on September 23, 2024, reporting a press release dated the same day. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release.
Why It Matters
This filing indicates Innate Pharma is providing an update to the market, likely containing important news for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, without disclosing new material financial information within the filing itself.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- September 23, 2024 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have submitted or are required to submit to a stock exchange.
What specific information is included in this 6-K filing?
This 6-K filing primarily serves to attach a press release dated September 23, 2024, as Exhibit 99.1.
Does this filing contain financial results for Innate Pharma?
No, this specific 6-K filing does not contain detailed financial results; it is an informational filing to attach a press release.
What is the filing date of this report?
The filing date of this report is September 23, 2024.
What is the principal executive office of Innate Pharma?
The principal executive office of Innate Pharma is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 9.5 · Accepted 2024-09-23 06:03:48
Filing Documents
- a6k-iphx240923.htm (6-K) — 8KB
- exhibit991-240923.htm (EX-99.1) — 17KB
- 0001598599-24-000072.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date September 23, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer